Bio pharma R&D category & biotech commercialization strategy
For bio pharma r&d category strategy, shifting from science‑first to patients‑first is crucial. Data challenges assumptions (e.g., redefining target physicians). Market access is non‑negotiable; without reimbursement readiness, prescriptions fail. For more info: https://www.zs.com/insights/bi....opharma-commercializ